AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Kim Julie So-Young sold $1.5M of TAK

Kim Julie So-Young (President and CEO) sold 89,090 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($1.52M total) on 2026-08-10.

Original reporting
SEC EDGAR · Kim Julie So-Young
Published Aug 13, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change earnings, guidance, or risk materially.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which can increase scrutiny, but the disclosed size ($1.52M) is still modest relative to typical large-cap valuation and lacks accompanying operational news.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-12 after the 2026-08-10 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Takeda CEO Kim Julie So-Young sold 89,090 shares in an open-market transaction valued at $1.52M, per a fresh Form 4 filing.

Expected impact

Likely minimal near-term price impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, and the text specifies an open-market sale with no 10b5-1 plan, but it does not provide new company performance, guidance, or regulatory/contract developments.

Market effects

Sector

No sector-level implications are disclosed; this is company-specific insider trading reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated versus fundamentals.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the Form 4 issuer.

  • insider
    Kim Julie So-Young

    President and CEO and reporting insider who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min